[HTML][HTML] PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
Background Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) occurs
frequently in prostate cancers. Preclinical evidence suggests that activation of PI3K/AKT …
frequently in prostate cancers. Preclinical evidence suggests that activation of PI3K/AKT …
Clinical impact of 68Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer …
…, K Limani, FX Otte, A Peltier, S Sideris… - BJU …, 2017 - Wiley Online Library
Objective To assess the impact of a novel molecular imaging technique, 68 Ga‐(HBED‐CC)‐prostate‐specific
membrane antigen (PSMA) positron emission tomography/computed …
membrane antigen (PSMA) positron emission tomography/computed …
[HTML][HTML] Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant …
…, D Bianchini, R Ferraldeschi, MP Kolinsky, S Sideris… - European urology, 2016 - Elsevier
Background The availability of multiple new treatments for metastatic castration-resistant
prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A …
prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A …
Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
…, D Marrinucci, Z Zafeiriou, P Flohr, S Sideris… - BJU …, 2017 - Wiley Online Library
Objectives To use a non‐biased assay for circulating tumour cells (CTCs) in patients with
prostate cancer (PCa) in order to identify non‐traditional CTC phenotypes potentially excluded …
prostate cancer (PCa) in order to identify non‐traditional CTC phenotypes potentially excluded …
68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy
…, I Karfis, G Critchi, NM Chanza, S Sideris… - Journal of Nuclear …, 2022 - Soc Nuclear Med
We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen (PSMA)
for response assessment in metastatic prostate cancer (PCa) patients treated with taxane…
for response assessment in metastatic prostate cancer (PCa) patients treated with taxane…
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration …
N Plouznikoff, C Artigas, S Sideris… - Annals of nuclear …, 2019 - Springer
Objective To investigate the association between Prostate-Specific Membrane Antigen (PSMA)
expression changes on positron emission tomography–computed tomography (PET/CT) …
expression changes on positron emission tomography–computed tomography (PET/CT) …
[HTML][HTML] Docetaxel treatment in PTEN-and ERG-aberrant metastatic prostate cancers
…, S Miranda, D Bianchini, Z Zafeiriou, S Sideris… - European Urology …, 2018 - Elsevier
Background Loss of PTEN is a common genomic aberration in castration-resistant prostate
cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to …
cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to …
[HTML][HTML] Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international …
…, A Mortazavi, MR Harrison, S Sideris… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background There is limited experience regarding the safety and efficacy of checkpoint
inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as …
inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as …
[HTML][HTML] Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer
S Sideris, F Aoun, M Zanaty… - Molecular and …, 2016 - spandidos-publications.com
The aim of the present study was to investigate the efficacy of paclitaxel following a first-line
cisplatin regimen in patients with metastatic bladder cancer. The present study …
cisplatin regimen in patients with metastatic bladder cancer. The present study …
[HTML][HTML] Early post-treatment prostate-specific antigen at 4 weeks and abiraterone and enzalutamide treatment for advanced prostate cancer: an international …
…, MI Saez, N Mehra, S Smeenk, S Sideris… - European urology …, 2020 - Elsevier
Background Declines in prostate-specific antigen (PSA) levels at 12 wk are used to evaluate
treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by …
treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by …